Abstract
6
viruses were further passaged to amplify the viral titer. Viral titers were determined by plaque 149 assay as described previously (41). All the recombinant viruses were verified by sequence 150 analysis.
152
Growth curves analysis. 153 Growth curve analysis has been carried out as described earlier (4). For multi-step growth curves 154 BHK cells were incubated with rVSV at an MOI of 0.01 for 1 h at 37°C. Following this 155 incubation, supernatant was removed, the monolayer was washed and fresh growth medium was 156 added. Supernatant was collected at predetermined time points (6, 12, 18 , 24, 30 and 36h), and 157 virus titer was determined by standard plaque assay.
159
Western blot, immunofluorescence and FACS analysis. 160 Western blot was done as described earlier (4). To detect viral protein expression levels, VSV- 
177
Binding assays, using wild type and echistatin displaying viruses, were carried out in suspension 178 as described earlier (5, 23). Briefly K562 cells were pelleted and washed with PBS three times.
179
Final cell pellet was dissolved in PBS, counted and aliquoted into different tubes. In vivo experiments.
192
All animal protocols were reviewed and approved by the Mayo Clinic Institutional Care and Use
193
Committee. BALB/c mice, female, 4-6 weeks old, were purchased from Jackson Laboratories. 
Virus neutralization assays.

253
A virus neutralization assay was performed to determine whether antibodies against echistatin which had no effect on wild-type virus infectivity (Fig. 3A ). This suggests that the echistatin 258 peptide is exposed on the surface of virion. On the other hand anti-VSV serum neutralized both 259 the viruses (Fig. 3B ).
260
Solid-phase receptor-binding assay.
261
To determine whether echistatin displaying VSV can bind to its specific receptor, we coated bound significantly better to integrin, v 3 than to the control integrin, 1 1 (Fig. 4 ). This study
266
shows that a ligand-displaying VSV has the ability to bind to its targeted receptor thorough the 267 displayed ligand and the binding is highly specific. 
Specific binding of echistatin displaying VSV to cells over-expressing targeted integrins.
283
We next investigated whether the virally displayed echistatin domain could mediate specific viral 284 binding to cells over expressing the targeted integrin, v 3. For this we incubated K562 (human 285 erythroleukemia) cells with VSV-WT and VSV-Echi9 for 30min at 37°C and also at 4°C for 2h.
286
After washing, the bound virus particles were subjected to RNA extraction and quantitative RT-
287
PCR. Analysis showed that affinity of unmodified and echistatin virus towards K562 wild-type 288 cells were almost the same (Fig. 6A) . On K562-v 5 cells, the affinity of VSV-Echi9 was 289 slightly higher than unmodified VSV (Fig. 6B) . At the same time affinity of VSV-Echi9 to 290 K562-v 3 cell surface increased significantly compared to unmodified virus (Fig. 6C) antibody ( Fig. 7D-E) . This experiment strongly suggests that the echistatin displaying VSV can 311 enter cells via the targeted integrin receptor even when the LDL receptor is effectively masked.
312
Oncolytic activity of targeted viruses in vivo after intravenous administration.
313
We next evaluated the oncolytic activity of the recombinant VSVs in mice with established showed that the EGFR-scFv was partially cleaved from the G protein whereas the Her2-scFv-G 338 protein fusion remained fully intact with no cleavage (Fig. 10C) (Fig.3) . At the same time specific binding of the echistatin displaying virus to v 3 integrin in a 387
solid-phase capture assay demonstrated that VSV can bind to a targeted receptor thorough a 388 polypeptide ligand displayed on its surface (Fig.4) . When the recombinant viruses were 389 incubated with wild-type and integrin overexpressing K562 cells, VSV-Echi-9 bound with 390 considerably higher affinity to K562-v 3 cells compared to wild-type virus (Fig.6 ). These data 391 further confirmed the higher affinity of echistatin displaying VSV to its targeted receptor.
392
A recent publication proposed and demonstrated that low-density lipoprotein receptor (LDLR)
393
and its family members serve as natural receptors for vesicular stomatitis virus (19). Therefore, 
403
The oncolytic potency of the ligand displaying viruses was tested in a mouse myeloma model.
404
Immunocompetent Balb/C mice bearing syngeneic subcutaneous mouse plasmactyomas were support to this idea but more detailed studies will be needed to confirm the impression.
420
We further tested the ability of the VSV G protein to tolerate large polypeptide insertions by 
